


CORRECTION

Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study

Atul T. Patel, Mark F. Lew, Khashayar Dashtipour, Stuart Isaacson, Robert A. Hauser, William Ondo, Pascal Maisonobe, Stefan Wietek, Bruce Rubin, Allison Brashear

In Fig 2, the delta and p-value are missing for the last available post-baseline assessment. The missing information reflects a statistically significant difference in the mean TWSTRS total score of aboBoNT-A vs placebo at the last available data point. Please see the correct Fig 2 here.




OPEN ACCESS

**Citation:** Patel AT, Lew MF, Dashtipour K, Isaacson S, Hauser RA, Ondo W, et al. (2021) Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study. PLoS ONE 16(4): e0250475. <https://doi.org/10.1371/journal.pone.0250475>

**Published:** April 14, 2021

**Copyright:** © 2021 Patel et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



**Fig 2. Mean TWSTRS total score.** aboBoNT-A = abobotulinumtoxinA; ITT = intent-to-treat (all randomized patients); last available\* = last available post-baseline (end of study or early withdrawal); TWSTRS = Toronto Western Spasmodic Torticollis Rating Scale; Δ = weighted overall treatment difference. Error lines indicate standard deviation. \*Last available = last available post-baseline (end of study or early withdrawal), mean (SD) study drug exposure: 62.6 (37.8) days.

<https://doi.org/10.1371/journal.pone.0250475.g001>

Reference

1. Patel AT, Lew MF, Dashtipour K, Isaacson S, Hauser RA, Ondo W, et al. (2021) Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study. PLoS ONE 16(2): e0245827. <https://doi.org/10.1371/journal.pone.0245827> PMID: 33524060